A Randomised, Multiple Dose, Dose Escalation, Double-Blind, Placebo-Controlled Phase I Study Investigating the Safety of ALK Tree Tablet in Adult Subjects With Birch Pollen Induced Rhinoconjunctivitis (With/Without Asthma)
Phase of Trial: Phase I
Latest Information Update: 28 Feb 2008
At a glance
- Drugs Birch pollen allergy immunotherapy (Primary)
- Indications Allergic rhinoconjunctivitis
- Focus Adverse reactions
- 28 Feb 2008 Status changed from recruiting to completed.
- 05 Oct 2007 New trial record.